Prior to leading In Vivo, Lucie was a senior editor at Scrip and Pink Sheet. She is responsible for the production of In Vivo online as well as the annual Outlook publication. Covering the biopharma space since 2012, Lucie writes feature articles on the topics of leadership, R&D, innovation and more. She also regularly attends industry events and moderates panel discussions on topics such as investment trends, women’s health and R&D hot topics.
Latest from Lucie Ellis-Taitt
King’s College London has released a freely available ‘Human Gut Microbiome Atlas’ to help researchers better understand how microorganisms in the gut impact disease.
Last year, In Vivo spotlighted some of biopharma’s most highly valued yet unpartnered assets. Now it’s time to see if deals have been struck and review how NPVs have changed.
Together, Merck’s heads of oncology and head of digital health outline their cross-functional strategy to enhance care for cancer patients through digital tools.
Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi.
Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.
Grey Wolf Therapeutics has secured $99m via an expanded series B financing to advance its antigen modulation approach in cancer and to further explore its use in autoimmune disease indications.